Quick Answer
KYNTRA BIO, INC. reported R&D Expense of $23.52 million for fiscal year 2025.
KYNTRA BIO, INC. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $23.52M | -75.4% |
| 2024 | $95.69M | -64.1% |
| 2023 | $266.47M | -10.2% |
| 2022 | $296.79M | -23.3% |
| 2021 | $387.04M | +53.0% |
| 2020 | $252.92M | +20.9% |
| 2019 | $209.26M | -11.3% |
| 2018 | $235.84M | +20.0% |
| 2017 | $196.52M | +5.0% |
| 2016 | $187.21M | -12.6% |
| 2015 | $214.09M | +42.0% |
| 2014 | $150.79M | +75.9% |
| 2013 | $85.71M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $1.21M | -93.9% | -79.4% |
| June 30, 2025 | $5.87M | -81.9% | -36.1% |
| March 31, 2025 | $9.18M | -74.9% | -54.1% |
| September 30, 2024 | $19.97M | -67.4% | -38.3% |
| June 30, 2024 | $32.36M | -66.1% | -11.3% |
| March 31, 2024 | $36.49M | -51.0% | -40.4% |
| September 30, 2023 | $61.19M | -18.6% | -35.9% |
| June 30, 2023 | $95.48M | +34.5% | +28.2% |
- KYNTRA BIO, INC. showed a decrease of -75.4% in R&D Expense compared to the prior fiscal year.
- Over the 2013–2025 period, KYNTRA BIO, INC.’s r&d expense has declined by 72.6% (from $85.71 million to $23.52 million).
- The most recent figure is from KYNTRA BIO, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 16, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: